BRCA2 oncogenic variants

About

Biomarker type: Somatic variant

Gene context: BRCA2

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations Biomarkers Cancer types Therapies
FDA (2) HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (2) HC (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Olaparib
FDA (2) HC (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
FDA (2) HC (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone